The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. The CGCI-NHL study characterized B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
The TARGET Neuroblastoma projects used comprehensive molecular characterization analyses to determine the genetic changes that drive the initiation and progression of high-risk cases (stage 4, the tumor has metastasized to many locations). In addition, we characterized a set of 4S cases who have metastasis, but usually not to the bone marrow and the disease clinically resolves.
The TARGET Osteosarcoma project used comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of high-risk or hard-to-treat childhood cancers.
The TARGET Analysis Working Group (TAWG) uses comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of high-risk or hard-to-treat childhood cancers.
The TARGET Acute Lymphoblastic Leukemia projects uses comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of hard-to-treat childhood cancers. Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells, the cells in the body that normally fight infection.
